ZA201703207B - Methods of treating multiple sclerosis - Google Patents
Methods of treating multiple sclerosisInfo
- Publication number
- ZA201703207B ZA201703207B ZA2017/03207A ZA201703207A ZA201703207B ZA 201703207 B ZA201703207 B ZA 201703207B ZA 2017/03207 A ZA2017/03207 A ZA 2017/03207A ZA 201703207 A ZA201703207 A ZA 201703207A ZA 201703207 B ZA201703207 B ZA 201703207B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- multiple sclerosis
- treating multiple
- treating
- sclerosis
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Business, Economics & Management (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Educational Technology (AREA)
- Entrepreneurship & Innovation (AREA)
- Educational Administration (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080783P | 2014-11-17 | 2014-11-17 | |
| US201562140255P | 2015-03-30 | 2015-03-30 | |
| US201562232963P | 2015-09-25 | 2015-09-25 | |
| PCT/US2015/060850 WO2016081355A1 (en) | 2014-11-17 | 2015-11-16 | Methods of treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201703207B true ZA201703207B (en) | 2021-08-25 |
Family
ID=54771192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/03207A ZA201703207B (en) | 2014-11-17 | 2017-05-09 | Methods of treating multiple sclerosis |
Country Status (13)
| Country | Link |
|---|---|
| US (9) | US20170354630A1 (https=) |
| EP (3) | EP3804711A1 (https=) |
| JP (5) | JP6786486B2 (https=) |
| KR (3) | KR102299842B1 (https=) |
| CN (6) | CN115501218A (https=) |
| AU (4) | AU2015350213A1 (https=) |
| CA (1) | CA2967619C (https=) |
| EA (1) | EA038370B1 (https=) |
| IL (2) | IL269885B (https=) |
| MA (2) | MA40985A (https=) |
| MX (1) | MX2017006473A (https=) |
| WO (1) | WO2016081355A1 (https=) |
| ZA (1) | ZA201703207B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3650042A1 (en) | 2014-03-14 | 2020-05-13 | Biogen MA Inc. | Dimethyl fumarate and vaccination regimens |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| SG10201907291QA (en) | 2015-02-08 | 2019-09-27 | Alkermes Pharma Ireland Ltd | Monomethylfumarate prodrug compositions |
| CA3019132A1 (en) | 2016-04-01 | 2017-10-05 | NOHMs Technologies, Inc. | Modified ionic liquids containing phosphorus |
| WO2019018432A1 (en) | 2017-07-17 | 2019-01-24 | NOHMs Technologies, Inc. | ELECTROLYTES CONTAINING PHOSPHORUS |
| EP3956287B1 (en) * | 2019-04-17 | 2025-04-09 | Myto Therapeutics, Inc. | Prodrugs of monomethyl fumarate |
| AU2020283238B2 (en) * | 2019-05-31 | 2022-07-07 | Curacle Co., Ltd. | Enteric tablet containing dimethyl fumarate |
| TW202116297A (zh) * | 2019-07-03 | 2021-05-01 | 西班牙商布爾奴爾法碼有限公司 | 組合療法之方法、組成物與套組 |
| TW202131914A (zh) | 2019-10-30 | 2021-09-01 | 西班牙商布爾奴爾法碼有限公司 | 用於神經疾病或病狀的治療之新治療方案 |
| CN111440771A (zh) * | 2020-03-17 | 2020-07-24 | 中山大学附属第三医院 | 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系 |
| CA3182369A1 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
| KR102713565B1 (ko) * | 2020-11-27 | 2024-10-07 | 주식회사 뷰노 | 의료 영상 기반의 뇌백질 병변 탐지 방법 |
| WO2022203432A1 (ko) * | 2021-03-25 | 2022-09-29 | 주식회사 큐라클 | 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물 |
| KR102566549B1 (ko) * | 2021-06-08 | 2023-08-14 | 제이투에이치바이오텍 (주) | 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도 |
| US20250181224A1 (en) * | 2023-12-01 | 2025-06-05 | Lemon Inc. | Implementing dialog-based image editing |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| PL2316430T3 (pl) | 2004-10-08 | 2012-11-30 | Forward Pharma As | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego |
| US20070207141A1 (en) | 2006-02-28 | 2007-09-06 | Ivan Lieberburg | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| ES2599227T3 (es) * | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Neuroprotección en enfermedades desmielinizantes |
| RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| CN102906278A (zh) | 2010-01-11 | 2013-01-30 | 比奥根艾迪克Ma公司 | 用于jc病毒抗体的测定 |
| EP2713724A4 (en) | 2011-05-26 | 2015-03-11 | Biogen Idec Inc | METHODS OF TREATING MULTIPLE SCLEROSIS AND PRESERVING AND / OR INCREASING MYELINE CONTENT |
| DK2715352T3 (da) | 2011-05-31 | 2019-05-20 | Biogen Ma Inc | Fremgangsmåde til vurdering af risiko for pml |
| CN114146081A (zh) | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| WO2014031901A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of use for monomethyl fumarate and prodrugs thereof |
| WO2014071371A1 (en) | 2012-11-05 | 2014-05-08 | Xenoport, Inc. | Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate |
| WO2014096425A2 (en) | 2012-12-21 | 2014-06-26 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (mmf) |
| EP2934503B1 (en) | 2012-12-21 | 2019-04-10 | Biogen MA Inc. | Deuterium substituted fumarate derivatives |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US10501494B2 (en) | 2013-04-26 | 2019-12-10 | Creative Bio-Peptides | Uses of peptides to treat brain injury and disease |
| CA2919381A1 (en) | 2013-08-01 | 2015-02-05 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| ES2713157T3 (es) | 2014-02-28 | 2019-05-20 | Banner Life Sciences Llc | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| EP3650042A1 (en) | 2014-03-14 | 2020-05-13 | Biogen MA Inc. | Dimethyl fumarate and vaccination regimens |
| AU2015328676B2 (en) | 2014-10-08 | 2017-07-20 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| WO2017040272A1 (en) | 2015-08-31 | 2017-03-09 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| WO2017151184A1 (en) | 2016-02-29 | 2017-09-08 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10523918B2 (en) | 2017-03-24 | 2019-12-31 | Samsung Electronics Co., Ltd. | System and method for depth map |
-
2015
- 2015-11-15 MA MA040985A patent/MA40985A/fr unknown
- 2015-11-16 CN CN202211204459.4A patent/CN115501218A/zh active Pending
- 2015-11-16 AU AU2015350213A patent/AU2015350213A1/en not_active Abandoned
- 2015-11-16 CN CN201580072773.3A patent/CN107106530A/zh active Pending
- 2015-11-16 CN CN202110623846.0A patent/CN113368091A/zh active Pending
- 2015-11-16 EP EP20195649.7A patent/EP3804711A1/en not_active Withdrawn
- 2015-11-16 CA CA2967619A patent/CA2967619C/en active Active
- 2015-11-16 CN CN202211204481.9A patent/CN115531366A/zh active Pending
- 2015-11-16 CN CN202110624861.7A patent/CN113368093A/zh active Pending
- 2015-11-16 EA EA201791101A patent/EA038370B1/ru unknown
- 2015-11-16 JP JP2017526549A patent/JP6786486B2/ja active Active
- 2015-11-16 KR KR1020177016298A patent/KR102299842B1/ko not_active Expired - Fee Related
- 2015-11-16 MA MA053882A patent/MA53882A/fr unknown
- 2015-11-16 CN CN202110623848.XA patent/CN113368092A/zh active Pending
- 2015-11-16 KR KR1020217028154A patent/KR20210111362A/ko not_active Ceased
- 2015-11-16 MX MX2017006473A patent/MX2017006473A/es unknown
- 2015-11-16 US US15/527,252 patent/US20170354630A1/en not_active Abandoned
- 2015-11-16 KR KR1020247007355A patent/KR20240035912A/ko not_active Ceased
- 2015-11-16 EP EP15804260.6A patent/EP3220907A1/en not_active Ceased
- 2015-11-16 EP EP22214115.2A patent/EP4215191A1/en active Pending
- 2015-11-16 WO PCT/US2015/060850 patent/WO2016081355A1/en not_active Ceased
- 2015-11-16 IL IL269885A patent/IL269885B/en unknown
-
2017
- 2017-05-09 ZA ZA2017/03207A patent/ZA201703207B/en unknown
- 2017-05-15 IL IL252296A patent/IL252296B/en unknown
- 2017-07-11 US US15/647,036 patent/US20180000770A1/en not_active Abandoned
- 2017-07-11 US US15/647,016 patent/US11129806B2/en active Active
-
2018
- 2018-07-24 US US16/043,641 patent/US20190008817A1/en not_active Abandoned
- 2018-10-29 US US16/173,723 patent/US10959972B2/en active Active
- 2018-11-27 JP JP2018221109A patent/JP6830941B2/ja active Active
-
2020
- 2020-07-22 US US16/936,398 patent/US11007166B2/en active Active
- 2020-09-08 JP JP2020150484A patent/JP2020196760A/ja not_active Withdrawn
- 2020-09-24 AU AU2020239734A patent/AU2020239734A1/en not_active Abandoned
- 2020-10-15 US US17/071,740 patent/US11007167B2/en active Active
-
2021
- 2021-05-17 US US17/321,788 patent/US11246850B2/en active Active
- 2021-11-15 AU AU2021269298A patent/AU2021269298A1/en not_active Abandoned
-
2022
- 2022-09-13 JP JP2022145173A patent/JP2022168243A/ja not_active Withdrawn
-
2024
- 2024-05-23 AU AU2024203437A patent/AU2024203437A1/en active Pending
-
2025
- 2025-02-07 US US19/048,181 patent/US20260007627A1/en active Pending
- 2025-05-12 JP JP2025079812A patent/JP2025109834A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
| IL279627A (en) | A method for treating depression | |
| IL252296A0 (en) | Methods for treating multiple sclerosis | |
| GB201701673D0 (en) | Methods of well treatment | |
| SG11201701723XA (en) | Methods of treating liver disease | |
| HUE061672T2 (hu) | Glikán-interakcióban lévõ vegyületek és felhasználási módszerek | |
| PT3089971T (pt) | Compostos e métodos de utilização | |
| ZA201706059B (en) | Method of treatment with tradipitant | |
| IL256207B (en) | Methods for treating multiple sclerosis | |
| GB201410116D0 (en) | Method of treatment | |
| GB2522719B (en) | Method of manufacture | |
| PL3220952T3 (pl) | Sposób leczenia lub zapobiegania udarowi | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| IL253028A0 (en) | treatment method | |
| IL253847A0 (en) | Methods of treating diseases | |
| SG11201610243YA (en) | Treatment of severe hypertriglyceridemia | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201604627D0 (en) | Improved method of FT-IMS | |
| IL265259A (en) | Treatment of multiple sclerosis with chs-131 | |
| GB2522716B (en) | Method of manufacture | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| SG11201710199PA (en) | Methods of treating multiple sclerosis | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201421980D0 (en) | Method of treatment |